重组人脑利钠肽在急性失代偿性心衰临床治疗中的有效性和安全性分析  

作　　者：吴昊[1] 尚佳[1] 赵建全[1] 刘永俊[1] 蒙淑红[1] 

机构地区：[1]内蒙古巴彦淖尔市医院心内一科,内蒙古巴彦淖尔015000

出　　处：《国际心血管病杂志》2017年第A01期213-213,共1页International Journal of Cardiovascular Disease

摘　　要：目的：分析重组人脑利钠肽（rhBNP）在急性失代偿性心表临床治疗中的有效性和安全性。方法：采用数字随机法把2015年7月至2016年7月急性失代偿性心衰患者60例划分为两组（对照组=30例，给予常规治疗；研究组=30例，给予rhBNP治疗），对最终的治疗效果进行对比。结果：治疗后，研究组的呼吸固难缓解有效率显著优干对照组（P〈0．05）；两组射血分数均发生了改变．研究组的改变情况优于对照组（P〈0．05）；研究组的不良反应率低于对照组（P〈0．05）。结论：rhBNP在急性失代偿性心表治疗中具有极高应用价值，临床各种指标情况改善良好。Objective ：To analyze the effectiveness and safety in the clinical treatment of acute decompensated heart failure in the treatment of acute decompensation. Method： 60 cases of acute decompensated heart failure patients were divided into two groups from 7/2015 -7/2016 （control group = 30 cases,given conventional treatment;study group=30 cases,given rhBNP treatment）, The final treatment results were compared. Results： After treatment, the effective rate of dyspnea in the study group was significantly better than that in the control group（P〈0.05）. The ejection fraction data of the two groups were changed, the change of the study group was better than that of the control group （P 〈0.05） .The adverse reaction rate was lower than control group（P〈0.05）.Conclusion; RhBNP in the treatment of acute decompensated heart failure has a high value, clinical indicators to improve the situation is good.

关 键 词：重组人脑利钠肽 急性失代偿性心衰 有效性 安全性 

分 类 号：R977[医药卫生—药品]